Risk of Venous Thromboembolism in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase.
Hussein AwadaAdel Hajj AliFaiz AnwerRaza ShahzadSandra MazzoniLouis WilliamsChakra ChaulagainBetty HamiltonCraig SauterJack KhouriPublished in: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2023)
Venous thromboembolism (VTE) is a serious complication commonly experienced in cancer patients. Incidence of VTE typically brings poor prognosis as it represents the second most common cause of mortality in cancer patients just after the malignancy itself. Studies suggest that multiple myeloma (MM) is among the malignancies with further enhanced risk of VTE, especially in patients undergoing autologous hematopoietic cell transplantation (AHCT). However, risk factors and preventative approaches remain poorly explored. Here, we explore the incidence of VTE in MM patients undergoing AHCT, while also highlighting risk factors and preventions that may aid in preventing VTE in patients who are at higher risk.
Keyphrases
- venous thromboembolism
- risk factors
- direct oral anticoagulants
- poor prognosis
- patients undergoing
- end stage renal disease
- multiple myeloma
- chronic kidney disease
- newly diagnosed
- ejection fraction
- bone marrow
- long non coding rna
- type diabetes
- coronary artery disease
- cell therapy
- cardiovascular events
- mesenchymal stem cells
- case control
- patient reported outcomes